The DUSP1 Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-mediated gene disruption model in which the DUSP1 locus is targeted across a heterogeneous cell population, yielding a polyclonal knockout pool. This product eliminates DUSP1 protein expression, abolishing its phosphatase activity toward MAP kinases without clonal selection, providing a versatile tool for interrogating MAPK pathway dynamics in a cancer cell context. As a polyclonal knockout population, it preserves natural genetic variation, making it suitable for experiments where clonal homogeneity is not required, such as pooled functional screens, stress response assays, and drug sensitivity profiling.
The parental HeLa cell line is an immortalized epithelial line derived from an HPV18-positive cervical adenocarcinoma, widely established as a model for cancer biology, signal transduction, and therapeutic response studies. HeLa cells exhibit robust MAPK signaling triggered by growth factors, cytokines, and stress stimuli, providing a relevant background to assess the consequences of DUSP1 loss. Their ease of culture and well-characterized molecular landscape make them a preferred system for dissecting phosphatase-mediated regulation of oncogenic pathways.
DUSP1 encodes a dual-specificity phosphatase that dephosphorylates tyrosine and threonine residues within the activation loop of MAP kinases, thereby inactivating MAPK1/ERK2, MAPK8/JNK1, and MAPK14/p38 alpha. DUSP1 expression is induced by mitogens such as EGF and PDGF, stress stimuli including TNF-alpha, and ERK-mediated feedback, serving as an inducible negative regulator of MAPK cascades. Loss of DUSP1 leads to elevated phosphorylation of its substrates, enhancing downstream transcription factors ELK1, c-JUN, and ATF2, and sustaining proliferative, survival, and stress-responsive gene programs.
In the HeLa adenocarcinoma background, disruption of DUSP1 potentiates MAPK output, mimicking conditions associated with oncogenic hyperactivation and therapeutic resistance. This knockout model allows researchers to explore how unrestrained ERK, JNK, and p38 signaling alters cell cycle progression, apoptotic thresholds, and adaptive responses to chemotherapeutics. The polyclonal nature avoids biases imposed by single-cell derivation, making the cells particularly useful for studying heterogeneous tumor cell behaviors and for screening modulators of MAPK-dependent phenotypes.
Key applications include western blotting to monitor phospho-ERK, phospho-JNK, and phospho-p38 levels; RT-qPCR to quantify DUSP1 transcript loss; immunofluorescence to assess MAPK subcellular localization; and functional assays such as cell proliferation, apoptosis, and drug sensitivity testing. The DUSP1 Knockout HeLa Polyclonal Cells provide an essential platform for elucidating MAPK signaling networks and for identifying vulnerabilities in cancer cells that rely on DUSP1 for signal termination. For further details, please contact Ascent Research.
